Fabrication of Niclosamide loaded solid lipid nanoparticles:in vitrocharacterization and comparativein vivoevaluation
Source abstract
Abstract
Niclosamide (NCS) is an oral anthelminthic drug having low solubility and hence low bioavailability. Current investigation shows an approach to fabricate solid lipid nanoparticles (SLNs) of NCS and evaluated for pharmaceutical, in vitro and in vivo characterization. NFM-3 showed particle size 204.2 ± 2.2 nm, polydispersity index 0.328 ± 0.02 and zeta potential -33.16 ± 2 mV. Entrapment efficiency and drug loading capacity were 84.4 ± 0.02% and 5.27 ± 0.03%, respectively. Scanning electron microscopy image indicated that particles were nanoranged. DSC and P-XRD results showed change in physicochemical properties of NCS. FT-IR spectra confirmed compatibility between NCS and excipients. The drug release profile showed sustained release (93.21%) of NCS in 12 h. Different kinetic models showed zero-order kinetics and Case-II transport mechanism. Study showed maximum stability at refrigerated temperature. In vivo pharmacokinetic study showed 2.15-fold increase in NCS peak plasma concentration as solid lipid nanoparticle formulation (NFM-3) compared to commercial product while relative bioavailability was 11.08. Results including in vitro and in vivo release studies of NCS confirmed that SLNs system is suitable to improve oral delivery of NCS with increased aqueous solubility, permeability and finally bioavailability.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmacy, University of Malakand, Chakdara, Pakistan;
Nano-Biotech Group (IBD), National Institute for Biotechnology and Genetic Engineering, Faisalabad, Pakistan
References (48)
Show source-provided references
1. 10.1016/j.jconrel.2012.04.00910.1016/j.jconrel.2012.04.009 ↗
2. 10.1016/j.jsps.2017.01.00610.1016/j.jsps.2017.01.006 ↗
3. 10.1007/s11051-008-9402-310.1007/s11051-008-9402-3 ↗
4. Fulekar M. · 2010
5. 10.3109/21691401.2016.116040210.3109/21691401.2016.1160402 ↗
6. Patidar A · Int J Pharm Pharm Sci · 2010 · 2 · 30
7. 10.1186/s40199-015-0128-310.1186/s40199-015-0128-3 ↗
8. 10.5732/cjc.011.1029010.5732/cjc.011.10290 ↗
9. 10.1016/S0099-5428(05)32002-810.1016/S0099-5428(05)32002-8 ↗
10. 10.1016/j.dyepig.2010.08.00210.1016/j.dyepig.2010.08.002 ↗
11. Weinbach EC, Garbus J. Mechanism of action of reagents that uncouple oxidative phosphorylation. Nature. 1969;221:1016–1018.10.1038/2211016a0 ↗
12. 10.18632/oncotarget.711310.18632/oncotarget.7113 ↗
13. 10.1158/0008-5472.CAN-10-397810.1158/0008-5472.CAN-10-3978 ↗
14. Whitesell JK. The Merck Index, CD-ROM (Macintosh): an encyclopedia of chemicals, drugs & biologicals. In: Budavari S, O'Neill M, Smith A, et al., editors. (Merck & Co., Inc.). New York: Chapman & Hall; 1997. $250.00. ISBN 0-412-75940-3. Washington, DC: ACS Publications; 1998.10.1021/ja975911w ↗
15. 10.1021/ml300308210.1021/ml3003082 ↗
16. 10.2147/IJN.S6714710.2147/IJN.S67147 ↗
17. 10.1016/j.jfoodeng.2014.06.01510.1016/j.jfoodeng.2014.06.015 ↗
18. 10.1016/j.ejps.2004.10.00810.1016/j.ejps.2004.10.008 ↗
19. 10.1016/j.addr.2006.09.01710.1016/j.addr.2006.09.017 ↗
20. Preet Kaur S, Rao R, Hussain A, et al. Preparation and characterization of rivastigmine loaded chitosan nanoparticles. J Pharm Sci Res. 2011;3:1227–1232.
21. 10.1016/S0939-6411(03)00020-110.1016/S0939-6411(03)00020-1 ↗
22. 10.3109/21691401.2014.94464510.3109/21691401.2014.944645 ↗
23. 10.1016/j.ejpb.2008.05.00810.1016/j.ejpb.2008.05.008 ↗
24. 10.1186/2008-2231-20-9310.1186/2008-2231-20-93 ↗
25. 10.1186/s40199-015-0128-310.1186/s40199-015-0128-3 ↗
26. 10.1002/047010631X10.1002/047010631X ↗
27. 10.1016/j.addr.2007.04.00410.1016/j.addr.2007.04.004 ↗
28. 10.1016/j.ijpharm.2010.01.00910.1016/j.ijpharm.2010.01.009 ↗
29. Daabees H. Selective differential spectrophotometric methods for determination of niclosamide and drotaverine hydrochloride. J Anal Lett. 2000;33:639–656.10.1080/00032710008543080 ↗
30. 10.1016/S0939-6411(97)00150-110.1016/S0939-6411(97)00150-1 ↗
31. 10.1080/1082607070173913210.1080/10826070701739132 ↗
32. 10.1007/BF0106210810.1007/BF01062108 ↗
33. 10.1208/pt05011210.1208/pt050112 ↗
34. 10.18433/J3D59T10.18433/J3D59T ↗
35. Kumar PP · Int Organ Sci Res J Pharm · 2012 · 2 · 23
36. 10.1166/jnn.2015.1169610.1166/jnn.2015.11696 ↗
37. 10.1016/j.jconrel.2010.10.00710.1016/j.jconrel.2010.10.007 ↗
38. 10.1016/j.ijpharm.2006.08.00710.1016/j.ijpharm.2006.08.007 ↗
39. 10.1166/jnn.2017.1379910.1166/jnn.2017.13799 ↗
40. 10.1002/jps.1047110.1002/jps.10471 ↗
41. 10.2147/IJN.S1681510.2147/IJN.S16815 ↗
42. 10.1021/cg400047310.1021/cg4000473 ↗
43. 10.1016/S0928-0987(01)00095-110.1016/S0928-0987(01)00095-1 ↗
44. 10.1016/S0939-6411(97)00097-010.1016/S0939-6411(97)00097-0 ↗
45. 10.1016/S0378-5173(03)00087-510.1016/S0378-5173(03)00087-5 ↗
46. 10.1016/j.jconrel.2005.05.01610.1016/j.jconrel.2005.05.016 ↗
47. 10.1016/j.jconrel.2005.11.00910.1016/j.jconrel.2005.11.009 ↗
48. 10.1016/S0168-3659(99)00007-310.1016/S0168-3659(99)00007-3 ↗